RecruitingPhase 2NCT04522544

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Studying Pediatric hepatocellular carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Principal Investigator
Salah-Eddin Al-Batran, Prof. Dr.
Frankfurter Institut für Klinische Krebsforschung IKF GmbH
Intervention
Tremelimumab(drug)
Enrollment
55 enrolled
Eligibility
18 years · All sexes
Timeline
20202027

Study locations (12)

Collaborators

AstraZeneca · Hannover Medical School

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04522544 on ClinicalTrials.gov

Other trials for Pediatric hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Pediatric hepatocellular carcinoma

← Back to all trials